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Abstract
Objective—The objectives of this study were to determine the rate of testosterone replacement 
therapy (TRT) initiation, TRT predictors and associated monitoring in HIV-infected men.
Design—A multisite cohort study.
Methods—We examined TRT initiation rates and monitoring among adult HIV-infected men in 
routine care at seven sites in the Centers for AIDS Research (CFAR) Network of Integrated 
Clinical Systems (CNICS) from 1996 to 2011. We determined TRT predictors using Cox 
regression modelling.
Results—Of 14 454 men meeting inclusion criteria, TRT was initiated in 1482 (10%) with an 
initiation rate of 19.7/1000 person-years [95% confidence interval (95% CI) 18.7–20.7]. In the 
multivariable model, TRT was significantly associated with age at least 35 years, white race, 
diagnosis of AIDS wasting, hepatitis C coinfection, protease inhibitor based antiretroviral therapy 
and nadir CD4+ cell count of 200 cells/µl or less. Overall, 1886 out of 14 454 (13%) had 
testosterone deficiency. Among those initiating TRT, 992 out of 1482 (67%) had a pre-TRT serum 
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total testosterone measured, and deficiency [<300 ng/dl (10.4 nmol/l)] was found in 360 out of 
1482 (24%). Post-TRT serum total testosterone was measured within 6 months of TRT initiation 
in 377 out of 1482 (25%) men.
Conclusion—TRT was common in HIV-infected men, though evidence for pre-TRT 
testosterone deficiency was lacking in 76%. Endocrine guidelines for post-TRT monitoring were 
uncommonly followed. Given cardiovascular and other risks associated with TRT, efforts should 
focus on understanding factors driving these TRT practices in HIV-infected men.
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Background
Global testosterone sales have increased 12-fold over the last decade, and the USA is the 
second leading consumer worldwide [1]. Androgen use tripled from 2001 to 2011 in the 
U.S., with 2.9% of men over 40 years of age on testosterone replacement therapy (TRT) [2]. 
Establishing biochemical testosterone deficiency is recommended before TRT initiation [3], 
yet up to 83% of men on TRT lack pretreatment testosterone measurements [4]. Direct-to-
consumer marketing and the availability of specialty clinics and transdermal preparations 
may contribute to TRT overuse in the USA [1,5,6]. This is concerning in light of recent 
studies suggesting that TRT may increase the risk of cardiovascular events [7,8], including 
myocardial infarction [9,10], stroke [10], thrombosis [11] and death [10], though these 
remain areas of ongoing investigation.
HIV is associated with testosterone deficiency [12] in up to 70% of men, a finding that 
persists despite successful antiretroviral therapy (ART) [13], and hypogonadism is expected 
to increase, as this population continues to age [14]. Yet, little is known about TRT among 
HIV-infected men. In a report from the early ART-era, TRT prevalence was 19%, though 
pre-TRT testosterone deficiency and post-TRT monitoring were not assessed [15]. In this 
report, we describe TRT initiation rates and predictors and associated monitoring among 
HIV-infected men in a large, multicentre U.S. cohort.
Materials and methods
The Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS) 
electronically collects and standardizes socio-demographic, clinical, laboratory and 
medication data from inpatient and outpatient encounters of over 28 000 HIV-infected 
individuals at eight US sites [16]. We performed a cohort study of adult HIV-infected men 
seen at one of the seven CNICS clinical sites in which TRT data were available from 1996 
to 2011. We excluded men on TRT prior to or within 30 days after cohort entry or with 
unknown TRT initiation date. TRT initiation was determined on the basis of documentation 
of transdermal (gel, patch or solution), intramuscular (testosterone cypionate or enanthate), 
oral or implantable formulations in pharmacy dispensing records, electronic medical records 
and/or chart abstractions. We defined testosterone deficiency as serum total testosterone less 
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than 300 ng/dl (10.4 nmol/l) based on US endocrinology practice guidelines [3]. 
Comorbidities were documented by the providers in the medical record.
We calculated TRT initiation rate as the number of TRT initiation events per person-years of 
follow-up time from cohort entry to initial TRT date, loss to follow-up or death. We 
assessed predictors of TRT initiation with univariable and multivariable Cox regression 
modelling. Statistical analyses were performed using SAS 9.2 (SAS Institute Inc., Cary, 
North Carolina, USA). This study was approved by the Northwestern University 
Institutional Review Board.
Results
There were 14 454 men without evidence of TRT prior to CNICS entry with 75 173 person-
years of follow-up time (Table 1). TRT was initiated in 1482 (10%) men at a median age of 
44 [interquartile range (IQR) 38–51] years. The median time between cohort enrolment and 
TRT initiation was 868 days (IQR 280–1907). Two TRT preparations were initiated on the 
same day for 102 men. Of the 1584 incident medications, 624 (39%) were intramuscular, 
503 (32%) were transdermal, one (0.1%) was oral and 456 (29%) were unspecified.
We calculated a TRT initiation rate of 19.7/1000 person-years [95% confidence interval 
(95% CI) 18.7–20.7]. Higher rates of TRT initiation were associated with age at least 35 
years, white race, MSM HIV risk factor, diagnosis of AIDS wasting, protease inhibitor 
based ART, nadir CD4+ T-lymphocyte cell count (CD4+) of 200 cells/µl or less, 
nonsmoking and absence of alcohol abuse.
In a multivariable model including all variables in the Table 1 and CNICS site, TRT 
initiation was independently associated with age at least 35 years, white race, diagnosis of 
AIDS wasting, hepatitis C coinfection, protease inhibitor-based ART and nadir CD4+ cell 
count of 200 cells/µl or less (Table 1).
During cohort follow-up, 6168 of 14 454 (43%) men had at least one serum total 
testosterone measurement, and 1886 of 6168 (31%) had testosterone deficiency. Of the men 
with testosterone deficiency, 1119 (59%) did not initiate TRT.
Among the 1482 men initiating TRT, pre-TRT serum total testosterone level was measured 
in 992 (67%), with a median average pretreatment level of 358 (IQR 248–499) ng/dl [12.4 
(IQR 8.6–17.3) nmol/l]. Pre-TRT testosterone deficiency was found in 360 (24%). Serum 
total testosterone was measured at least once after TRT initiation in 898 (61%), with a 
median maximum post-TRT level of 569 (IQR 370–841) ng/dl [19.7 (IQR 12.8–29.2) 
nmol/l]. Median time to first post-TRT serum total testosterone measurement was 303 (IQR 
104–885) days. The first post-TRT serum total testosterone measurement occurred within 6 
months of TRT initiation in 377 (25%) men.
Over half (55%, 812/1482) of those initiating TRT were over age 40. In this group, 273 
(34%) and 97 (12%) had pre and 6-month post-TRT prostate-specific antigen (PSA) 
measurements, respectively.
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In this large, multicentre cohort of HIV-infected men, the TRT initiation rate (19.7/1000 
person-years) was over 2.5 times higher than that reported from insurance claims for US 
adult men in 2011 (7.57/1000 person-years) [5].
Endocrine Society Clinical Practice Guidelines [3] state that TRT is indicated for 
symptomatic men with unequivocal biochemical androgen deficiency. In one-third 
(490/1482) of men initiating TRT in CNICS, pre-TRT serum total testosterone levels were 
unavailable or unmeasured. Only 360 of 1482 (24%) men initiating TRT had laboratory-
confirmed testosterone deficiency [serum total testosterone <300 ng/dl (10.4 nmol/l)], 
similar to rates from general male populations initiating TRT (12–40%) [5]. Further, only 
273 of 812 (34%) men over age 40 for whom pre-TRT PSA levels are recommended [3] 
underwent PSA testing, consistent with other reports (34.9% [4]). These data suggest that 
TRT may be commonly administered to HIV-infected men without adequate baseline 
laboratory evaluation and establishment of recommended indications.
We propose several reasons for higher TRT initiation rates among HIV-infected men. 
Symptomatology associated with hypogonadism, such as fatigue, psychosexual dysfunction 
and erectile dysfunction [2], may occur more commonly in HIV-infected men and prompt 
empiric TRT. HIV-infected men may also have greater opportunity to be offered TRT 
during frequent provider visits. In addition, AIDS wasting and low nadir CD4+ cell count, 
proxies for end-stage AIDS, predicted TRT in our study. TRT is indicated for HIV-infected 
men with low testosterone and AIDS-associated weight loss [3]; however, only 4% ever had 
AIDS wasting, suggesting that this was not a major contributor. Finally, protease inhibitor 
use was associated with TRT. Older protease inhibitor based ART is implicated in 
lipodystrophy and fat redistribution. Body morphologic changes associated with 
lipodystrophy can be similar to those of testosterone deficiency and may lead to TRT. 
Protease inhibitors may also enhance peripheral conversion of testosterone to estradiol, 
resulting in symptoms of hypogonadism [12].
We found inadequate post-TRT monitoring. Endocrinology guidelines recommend 
monitoring serum testosterone levels 3–6 months after TRT initiation [3], yet these 
measurements were lacking in 39% and obtained within the first 6 months in only 25% of 
men. Although some patients may have declined testing or received testing outside CNICS, 
these findings strongly suggest that that HIV providers may not follow recommended 
monitoring guidelines.
CNICS is limited by the ability to consistently capture data on serum testosterone and PSA 
testing and TRT obtained from providers outside clinical sites, potentially leading to 
underreporting of pre-TRT deficiency, post-TRT monitoring and/or TRT initiation. This 
could partially explain the high proportion (59%) of men with biochemical testosterone 
deficiency in the cohort who did not appear to initiate TRT. In addition, it is possible that 
alternative diagnostic tests were used for determining pre-TRT testosterone deficiency and 
post-TRT monitoring. Elevations in sex-hormone binding globulin (SHBG) in HIV-infected 
men may result in low serum-free (bioavailable) testosterone but seemingly normal serum 
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total testosterone [17,18], prompting some to utilize serum-free testosterone to screen for 
deficiency and/or monitor response to TRT in men with HIV [19]. Serum-free testosterone 
and SHBG laboratory data are inconsistently captured in CNICS and were not utilized for 
these analyses, which could have contributed to low observed rates of pre-TRT testosterone 
deficiency and post-TRT testosterone monitoring. We are also unable to verify whether 
serum testosterone measurements were obtained as recommended in the morning, when 
levels are most predictable [3]. Finally, due to data limitations, we cannot comment on 
symptoms, other patient factors or provider factors driving these TRT practices. The 
strength of our study is comprehensive laboratory, clinical and medication data from a large 
and geographically diverse cohort reflecting routine care of HIV-infected men in the USA.
In conclusion, HIV-infected men initiate TRT at high rates, potentially without baseline 
testosterone deficiency or recommended posttreatment monitoring. Overuse of TRT can 
increase the risks of erythrocytosis, metastatic prostate cancer, reduced sperm production 
and infertility [3]. Further, TRT has been associated with myocardial infarction in those with 
preexisting cardiovascular disease [9], which may be conferred by HIV infection itself 
[20,21]. TRT data capture and reporting should be prioritized in HIV research agendas, and 
subsequent studies will evaluate outcomes and causes of TRT in HIV-infected men.
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Table 1
Testosterone replacement therapy initiation rates and rate ratios of HIV-infected men in Centers for AIDS 
Research Network of Integrated Clinical Systems stratified by characteristics at cohort entry.
N TRT events Person-years (py) Rate (per 1000 py) IRR 95% CI HRa 95% CI
Overall 14 454 1482 75 173 19.7 – 18.7–20.7 – –
Age (years)
  ≤34 4795 323 25 231 12.8 1.0 – 1.0 –
  35–50 8042 959 42 865 22.4 1.75 1.54–1.98 1.58 1.37–1.83
  >50 1617 200 7077 28.3 2.21 1.85–2.63 1.82 1.48–2.24
Race
  Nonwhite 7196 508 37 063 13.7 1.0 – 1.0 –
  White 7258 974 38 110 25.6 1.86 1.68–2.07 1.72 1.51–1.96
HIV risk factor
  Non-MSM 4535 391 24 439 16.0 1.0 – 1.0 –
  MSM 9919 1091 50 734 21.5 1.34 1.20–1.51 1.12 0.97–1.29
AIDS wasting
  No 13 940 1371 72 390 18.9 1.0 – 1.0 –
  Yes 514 111 2784 39.9 2.11 1.74–2.55 2.07 1.64–2.60
Hepatitis B
  No 13 361 1354 68 930 19.6 1.0 – 1.0 –
  Yes 1093 128 6244 20.5 1.04 0.87–1.25 1.10 0.92–1.37
Hepatitis C
  No 10 983 1099 55 508 19.8 1.0 – 1.0 –
  Yes 3471 383 19 666 19.5 0.98 0.88–1.10 1.2 1.04–1.38
ART type
  None 4335 370 24 097 15.4 1.0 – 1.0 –
  Non-PI-based 4819 397 22 559 17.6 1.15 1.00–1.32 1.02 0.86–1.21
  PI-based 5300 715 28 517 25.1 1.63 1.44–1.85 1.44 1.23–1.68
Nadir CD4+ cell count (cells/µl)
  ≥500 2464 212 12 221 17.4 1.0 – 1.0 –
  350 – 499 2515 221 12 965 17.1 0.98 0.82–1.18 1.02 0.83–1.26
  201 – 349 3434 334 18 156 18.4 1.06 0.89–1.26 1.10 0.90–1.34
  ≤200 6041 715 31 831 22.5 1.29 1.11–1.51 1.23 1.02–1.49
HIV RNA (copies/ml)
  ≤500 1983 195 8858 22.0 1.0 – 1.0 –
  >500 12 471 1287 66 316 19.4 0.88 0.76–1.02 1.03 0.86–1.23
BMI (kg/m2)
  ≥30.0 1329 139 6329 22.0 1.0 – 1.0 –
  25.0–29.9 3486 371 17 799 20.8 0.95 0.78–1.15 0.87 0.72–1.06
  18.5–24.9 5891 630 29 636 21.3 0.97 0.81–1.16 0.90 0.74–1.08
  <18.5 (underweight) 416 51 1948 26.2 1.19 0.87–1.64 1.14 0.82–1.58
  Unknown 3332 291 19 461 15.0 0.68 0.56–0.83 – –
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N TRT events Person-years (py) Rate (per 1000 py) IRR 95% CI HRa 95% CI
Smoking ever
  Yes 5566 483 32 422 14.9 1.0 – 1.0 –
  Never or unknown 8888 999 42 752 23.4 1.57 1.41–1.75 1.13 0.98–1.31
Alcohol abuse ever
  Yes 2867 265 17 097 15.5 1.0 – 1.0 –
  Never or unknown 11 587 1217 58 076 21.0 1.35 1.19–1.54 0.90 0.76–1.06
ART, antiretroviral therapy; CD4+, CD4+ T-lymphocyte cell count; PI, protease inhibitor.
a
Multivariable Cox regression modelling using all variables listed in the table and CNICS site.
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